Peptide Atlas · Peptide

CJC-1295 DAC

CJC-1295 is a tetrasubstituted form of human growth hormone-releasing factor (1-29) with an added maleimidopropionamide derivative of lysine at its C-terminus, designed to bind serum albumin after injection and so extend its plasma half-life.

emerging

provisional
PubChem 91971820
2 citations
0 discussions
0 followers

Follow this molecule Ask the Hunter-Gatherer

What the evidence says

six tiers, never blended

emerging — human data exists, and it is thin or contested

every claim resolves to its source

All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.

Evidence, kept apart

The Atlas never mixes evidence types into one blob. Each claim below carries the tier it actually sits in; an unresolved citation is shown and does not move the page.

Evidence map for CJC-1295 DAC. Tier reflects study design, not enthusiasm.
Claim	Tier	Source
Randomized, placebo-controlled ascending-dose trials in healthy adults	emerging	pmid 16352683
hGRF(1-29)-albumin bioconjugates; identification of CJC-1295	preclinical	pmid 15817669

Unanswered questions

No open questions on file. Either everything about this molecule is known, or nobody has admitted what is not.

Negative findings

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.